A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody–Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy
- 23 October 2018
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 42 (2) , 208-214
Abstract
OBJECTIVE Progression to insulin therapy in clinically diagnosed type 2 diabetes is highly variable. GAD65 autoantibodies (GADA) are associated with faster progression, but their predictive value is limited. We aimed to determine if a type 1 diabetes genetic risk score (T1D GRS) could predict rapid progression to insulin treatment over and above GADA testing. RESEARCH DESIGN AND METHODS We examined the relationship among T1D GRS, GADA (negative or positive), and rapid insulin requirement (within 5 years) using Kaplan-Meier survival analysis and Cox regression in 8,608 participants with clinical type 2 diabetes (onset >35 years and treated without insulin for ≥6 months). T1D GRS was both analyzed continuously (as standardized scores) and categorized based on previously reported centiles of a population with type 1 diabetes (50th [high]). RESULTS In GADA-positive participants (3.3%), those with higher T1D GRS progressed to insulin more quickly: probability of insulin requirement at 5 years (95% CI): 47.9% (35.0%, 62.78%) (high T1D GRS) vs. 27.6% (20.5%, 36.5%) (medium T1D GRS) vs. 17.6% (11.2%, 27.2%) (low T1D GRS); P = 0.001. In contrast, T1D GRS did not predict rapid insulin requirement in GADA-negative participants (P = 0.4). In Cox regression analysis with adjustment for age of diagnosis, BMI, and cohort, T1D GRS was independently associated with time to insulin only in the presence of GADA: hazard ratio per SD increase was 1.48 (1.15, 1.90); P = 0.002. CONCLUSIONS A T1D GRS alters the clinical implications of a positive GADA test in patients with clinical type 2 diabetes and is independent of and additive to clinical features.Keywords
This publication has 37 references indexed in Scilit:
- Islet autoantibodies can discriminate maturity‐onset diabetes of the young (MODY) from Type 1 diabetesDiabetic Medicine, 2011
- Harmonization of Glutamic Acid Decarboxylase and Islet Antigen-2 Autoantibody Assays for National Institute of Diabetes and Digestive and Kidney Diseases ConsortiaThe Journal of Clinical Endocrinology & Metabolism, 2010
- Defining and Characterizing the Progression of Type 2 DiabetesDiabetes Care, 2009
- A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association StudiesPLOS Genetics, 2009
- GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77Diabetologia, 2007
- Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controlsNature, 2007
- Islet antibodies and remaining β‐cell function 8 years after diagnosis of diabetes in young adults: a prospective follow‐up of the nationwide Diabetes Incidence Study in SwedenJournal of Internal Medicine, 2004
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996
- Islet Cell Antibodies Identify Latent Type I Diabetes in Patients Aged 35–75 Years at DiagnosisDiabetes, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958